Inovio announces first subject dosed with dMAb™ in first-ever human trial
Inovio in collaboration with The Wistar Institute and the University of Pennsylvania announced the first subject was dosed as part of the first-ever human study of Inovio's DNA-encoded monoclonal antibody technology. The study is funded fully by Bill & Melinda Gates Foundation. February 20, 2019